Alliance of Infinity Trade
Aprepitant
AIT Pharmaceuticals Division: Pioneering Supportive Care with Aprepitant
Introduction:
Welcome to AIT Pharmaceuticals Division, dedicated to advancing healthcare through innovative pharmaceutical solutions. We are pleased to introduce our Aprepitant Range, designed to provide effective supportive care for patients undergoing chemotherapy or experiencing other forms of nausea and vomiting. With a focus on quality and patient well-being, we strive to offer reliable medications that meet the highest standards of safety and efficacy.
Share
Pharmacokinetics and Pharmacodynamics:
Aprepitant is a selective neurokinin-1 (NK-1) receptor antagonist that exerts its antiemetic effects by blocking the action of substance P, a neurotransmitter involved in the vomiting reflex. By inhibiting substance P binding to NK-1 receptors in the central nervous system, aprepitant helps to prevent chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).
Drug Classification:
Aprepitant is classified as a neurokinin-1 (NK-1) receptor antagonist and is indicated for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). It is also used for the prevention of postoperative nausea and vomiting (PONV) following surgery.
Formulations:
Our Aprepitant Range is available in capsule form, with each capsule containing either 40 mg or 80 mg of aprepitant. The capsules are formulated for optimal absorption and efficacy in preventing nausea and vomiting associated with chemotherapy and surgery.
Indications:
Aprepitant capsules are indicated for the prevention of:
Acute and Delayed Nausea and Vomiting: Associated with highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC).
Postoperative Nausea and Vomiting (PONV): Following surgery.
Usage:
Aprepitant capsules should be taken orally with a full glass of water, preferably on an empty stomach, at least 1 hour before chemotherapy or surgery. Additional doses may be taken on subsequent days to prevent delayed nausea and vomiting, as directed by a healthcare provider.
Dosage:
The recommended dosage of aprepitant varies depending on the specific chemotherapy regimen and the risk of emesis. For highly emetogenic chemotherapy (HEC), the typical dosage is 125 mg on Day 1 and 80 mg once daily on Days 2 and 3. For moderately emetogenic chemotherapy (MEC), the recommended dosage is 125 mg on Day 1 followed by 80 mg once daily on Days 2 and 3.
Side Effects:
While aprepitant is generally well-tolerated, it may cause some side effects, including:
- Fatigue and weakness
- Dizziness or lightheadedness
- Headache
- Nausea, vomiting, or diarrhea
- Changes in taste
Injection site reactions (if administered intravenously)
It is important to inform your healthcare provider if you experience any persistent or severe side effects while taking aprepitant.
Packing Specifications:
Our Aprepitant capsules are conveniently packaged in blister packs containing 2 capsules each, ensuring ease of storage and administration.
Trust AIT Pharmaceuticals Division for effective supportive care solutions to manage chemotherapy-induced and postoperative nausea and vomiting. With our Aprepitant Range, patients can experience improved quality of life and enhanced comfort during treatment and recovery.
Reviews
There are no reviews yet.